These findings emphasized the necessity of repeated measurements and trajectory analyses of NT-proBNP in the management of CTD-PAH patients, especially a re-measurement at 3 months from baseline for patients with high-baseline NT-proBNP levels. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.